Effect of Purslane seeds in patients with nonalcoholic fatty liver disease

Effect of Purslane seeds on liver enzymes, lipid profile and FBS in patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090210826N14

Enrollment

Registered

2014-09-26

Start date

2014-04-04

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver. Nonalcoholic fatty liver disease (NAFLD)

Interventions

Intervention 1: Intervention group: using low caloric diet (kilo caloric/ body weight) - 500.15% protein, 55% carbohydrate, 30% fat.also they use10 gr purslane seed daily for 8 weeks. Intervention 2:

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 25 to75 years old body mass index>=25 distinction of the grade of fatty liver by sonography and understanding by doctor not pregnant or lactating do not have any other diseases like gastrointestinal, liver, renal or thyroid disease and diabetes individuals who are not under special diet and do not participate in another intervention do not use low caloric diet or drugs for decrease weight in 3 months do not use vitamin supplements 2 months ago do not change in drugs for reduce lipid and hypertension during the intervention Exclusion criteria: patients who are not using more than 30 percent of determined Purslane seeds sachet will excluded from study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver supersonic graphy. Timepoint: before & after intervention. Method of measurement: radiologic picture.;AST. Timepoint: before and after intervention. Method of measurement: blood sample.;ALT. Timepoint: before and after intervention. Method of measurement: blood sample.;Alkalin phosphat. Timepoint: before and after intervention. Method of measurement: blood sample.	—

Secondary

Measure	Time frame
Triglycerid. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;Insulin. Timepoint: before and after intervention. Method of measurement: blood sample.;Malon di aldehid. Timepoint: before and after intervention. Method of measurement: blood sample.;DPPH. Timepoint: before and after intervention. Method of measurement: blood sample.;Weight. Timepoint: before avd after intervention. Method of measurement: digital scale.;Hieght. Timepoint: before avd after intervention. Method of measurement: stadiometer,m.;Waist circumfrence. Timepoint: before avd after intervention. Method of measurement: meter,cm.;FBS. Timepoint: before and after intervention. Method of measurement: mg/dl.;Total cholestrol. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;LDL. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;HDL. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.	—

Measure

Time frame

Triglycerid. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;Insulin. Timepoint: before and after intervention. Method of measurement: blood sample.;Malon di aldehid. Timepoint: before and after intervention. Method of measurement: blood sample.;DPPH. Timepoint: before and after intervention. Method of measurement: blood sample.;Weight. Timepoint: before avd after intervention. Method of measurement: digital scale.;Hieght. Timepoint: before avd after intervention. Method of measurement: stadiometer,m.;Waist circumfrence. Timepoint: before avd after intervention. Method of measurement: meter,cm.;FBS. Timepoint: before and after intervention. Method of measurement: mg/dl.;Total cholestrol. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;LDL. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.;HDL. Timepoint: before and after intervention. Method of measurement: mgr/dl, blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Azade Najarzadeh

Yazd University of Medical Sciences

azadnajarzadeh@ssu.ac.ir+98 353820910014

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026